A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension (NCT03492177)
A Prospective, Multicenter, Open Label, Single Arm, Phase 2 Study to Investigate the Safety, Tolerability and Pharmacokinetics of Selexipag in Children With Pulmonary Arterial Hypertension
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (\>=) 2 to less than (˂) 18 years of age with Pulmonary Arterial Hypertension (PAH), by investigating the PK of selexipag and its active metabolite ACT-333679 in this population.
Who can join: Review the eligibility criteria below.
Location: Children'S Hospital Cardiac Care Center University Of Colorado — Aurora, Colorado
Age range: 2 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (34 Sites)
Showing the first 25 of 34 sites.
- Children'S Hospital Cardiac Care Center University Of Colorado — Aurora, Colorado
- University of Iowa Hospital — Iowa City, Iowa
- Seattle Children's Hospital — Seattle, Washington
- State Institution Republican Scientific And Practical Center For Pediatric Surgery — Minsk,
- Health Institution 4Th City Children'S Clinical Hospital — Minsk,
- UZ Gent — Ghent,
- Centre Hospitalier Sainte Justine — Montreal, Quebec
- Beijing Anzhen Hospital — Beijing,
- Shanghai Childrens Medical Center — Shanghai,
- CHU Arnaud de Villeneuve — Montpellier,
- Hôpital Necker - Enfants Malades — Paris,
- Chu Hopital Des Enfants — Toulouse,
- Universitätsklinikum Freiburg Zentrum — Freiburg im Breisgau,
- Gottsegen Gyorgy Orszagos Kardiologiai Intezet, Felnott kardiologiai osztaly — Budapest,
- Schneider Children's Medical Center — Petach Tikvah,
- Sheba Medical Center — Ramat Gan,
- Sarawak Heart Center — Kota Samarahan,
- Institut Jantung Negara (National Heart Institute) — Kuala Lumpur,
- Wojewodzki Szpital Specjalistyczny We Wroclawiu — Wroclaw,
- Kazan State Medical University — Kazan',
- Scientific and Research Institution of Cardiovascular Diseases Complex Problems — Kemerovo,
- Moscow Scientific Research Institute For Pediatrics And Childrens Surgery Of Rosmedtechnologies — Moscow,
- Saint Petersburg State Pediatric Medical University — Saint Petersburg,
- Almazov National Medical Research Center Of The Ministry Of Health Of The Russian Federation — Saint Petersburg,
- Samara Regional Clinical Cardiological Dispensary — Samara,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Pulmonary Arterial Hypertension
- A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION) — Aurora, Colorado
- A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension — Phoenix, Arizona
- Pulmonary Vascular Disease Phenomics Program PVDOMICS — Tucson, Arizona
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH) — Jacksonville, Florida
- ADAPT - A Patient Registry of the Real-world Use of Orenitram® — Fresno, California
Explore by condition: All Pulmonary Arterial Hypertension clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.